Vivacelle Bio, Inc.
- Year 2017 Finalist
- From Chicago, IL
- Website vivacellebio.com
Vivacelle Bio is developing VBI-1, a novel nanoparticle fluid to reverse adverse effects of blood loss. Preclinical studies demonstrate that VBI-1 is safer and more effective than current fluids used for resuscitation in shock. VBI-1 protects organs, while blood may cause organ damage. The worldwide market is estimated at $13 billion.
CS We are confident that the combination of an entrepreneurial environment in Buffalo that is committed to providing investment capital and other support, along with the outstanding preclinical and clinical research resources, will facilitate our success and survival. In addition, Buffalo has contract manufacturing facilities that have the capacity and expertise to manufacture VBI-1; we have already visited with them and had preliminary discussions.
Understand gravity and play the piano well.